pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 49 | Non-oncology: 31 Oncology: 18 |
| Under Consideration for Negotiation | 23 | Non-oncology: 15 Oncology: 8 |
| Completed Negotiations | 744 | With Letter of Intent: 641 Without agreement: 103 |
| Negotiations That Were Not Pursued | 108 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Enhertu (pTAP negotiation) | AstraZeneca Canada Inc. | As monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen | |
| Alecensaro | Hoffmann-La Roche Ltd. | adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). | |
| Tibsovo | Servier Canada Inc. | In combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy |